Drug Development Advisory Board
The Drug Development Advisory Board (DAB) at Simbec-Orion was established to offer our clients additional support and guidance in their drug development journey. All members of our DAB are independent of Simbec-Orion, and each are hand-picked as experts in their chosen fields.
These respected scientists utilise their individual areas of expertise to offer specialist insights to our clients, including supporting with aspects of study design and protocol development, regulatory advice, and interpretation of emerging study data.
Our DAB members include leading authorities in our core therapeutic areas of oncology and rare disease. Other individuals bring their extensive experience across all stages of the pharmaceutical development process, including non-clinical, first in human, drug metabolism, and pharmacokinetics.
Drug Development Advisory Board
Pierre Attali
Member of Drug Development Advisory Board
Simon Hutchings
Member of Drug Development Advisory Board
Art Gertel
Member of Drug Development Advisory Board
Jörn Klinger
Member of Drug Development Advisory Board
Marco Schmidt
Member of Drug Development Advisory Board
Alan Philips
Drug Development Advisory Board
Geoff Kitson
Vaccines & Infectious Disease Expert
Kirsty Wydenbach
Regulatory & Pharmaceutical Medicine Expert
David Jones
Pharmaco-toxicology Expert
Sarah Blagden
Oncology Scientific Advisory Board
Samson Fung
Oncology Scientific Advisory Board
Ahmad Awada
Oncology Scientific Advisory Board
Carlos Camozzi
Chair, Rare & Orphan Scientific Advisory Board
Alain Thibault
Chair, Oncology Scientific Advisory Board
Navigating the Regulatory Journey from Nonclinical to Early Phase Clinical Trials
Two-part webinar series: Two of our Scientific Advisory Board members presented a webinar series examining the transition from nonclinical to early clinical from a regulatory perspective and highlighting the key areas where your program can benefit from some forward thinking and planning for your next steps.
